ABSTRACT
Introductıon
chronic myeloid leukaemia (cMl) is a clonal haematological disease characterised by the presence of Philadelphia (Ph) chromosome which is the result of t(9;22)(q34;q11) translocation, in about 95% of cases. this reciprocal translocation leads to a rearrangement between the ABl gene on chromosome 9 and the BcR gene on chromosome 22. the resulting BcR-ABl fusion gene encodes a protein which has an increased tyrosine kinase activity and plays the major role in cMl pathogenesis (2, 11) .
Better understanding of molecular biology of the disease led to the introduction of imatinib mesylate, a potent ABl kinase inhibitor. With this agent, high rates of cytogenetic response are achieved in chronic phase cMl patients (1, 8) .
cytogenetic abnormalities other than Ph chromosome have been reported to occur during the natural course of cMl. occurrence of additional cytogenetic abnormalities in the Ph(+) cells is defined as clonal evolution (CE) and considered to be a preceding sign for acceleration. the most common additional chromosomal changes are +8 (34% of cases with additional chages), +Ph (30%), i(17q) (20%), +19 (13%), -Y (8% of males), +21 (7%), +17 (5%) and -7 (5%) and these abnormalities are denoted as the major route abnormalities (2, 4) . the aims of this study were to delineate the occurrence pattern of cytogenetic clonal evolution in our cohort of cMl patients and to investigate the impact on the course and prognosis of cMl.
Materıals and Methods
Definitions clonality assessments were made according to the rules of iScn (international System for human cytogenetic nomenclature) 1995/2005 (3, 4). Structural chromosome abnormalities and trisomies were defined as "clonal" if they were present in at least two metaphases. Monosomies were regarded clonal only if they exist in at least three cells. Samples carrying additional chromosomal abnormality only on one metaphase were rendered non-clonal and excluded. Cytogenetic responses to therapy were defined as follows (7) 19%) . the clinical data of the 20 cases with clonal evolution were reviewed in detail and compared to 7 cases with no or minor cytogenetic response without clonal evolution.
Study population
In total, 27 cases were evaluated in two groups. The first group included 20 patients with ce. At the time of imatinib treatment, their median age was 43 years (range: 18-73). 19 patients were in chronic phase and one (case 7) in an accelerated phase.
The median follow-up duration was 67 months (range: 27-177). Male to female ratio was 11/9. eleven patients (cases 1, 5, 8, 9, 10, 12, 13, 14, 16, 17 and 20) have been previously treated with hydroxyurea (hU) alone, six (cases 2, 3, 4, 6, 19) with inF including one in combination with cytarabine (ARA c) (case 18). the median follow-up duration after imatinib therapy was 34.5 months (range: 5-65). two of the patients (cases 1 and 2) underwent allogeneic stem cell transplantation. two patients (cases 3 and 9) with initial chronic and one (case 7) with accelerated phase cMl progressed to blastic phase and died of disease related causes. one patient (case 12) with poor cytogenetic response died of acute abdomen while on dasatinib for six months. of the 18 non-transplanted patients, three patients (cases 15, 14, 8) only achieved complete cytogenetic response on 400 mg/day imatinib with follow-up durations of 29, 52 and 77 months. one patient (case 19) in chronic phase cMl was lost to follow-up after 76 months of treatment with imatinib in PcR. one patient (case 11) responded to 600 mg imatinib and achieved partial cytogenetic response. in the remaning nine patients with chronic phase cMl showing no cytogenetic response imatinib was replaced with another thyrosine kinase inhibitor (8 on dasatinib (cases 5, 9, 10, 12, 16, 17, 18, 20), one on nilotinib (case 6) after intolerance to dasatinib). three of these patients (cases 9, 12, and 16) never achieved a cytogenetic response. case 5, achieved MinimalcR and case 17 achieved PcR at the 6 th month of dasatinib treatment. cases 10, 17, and 20 had achieved and lost their cytogenetic responses before dasatinib.
Seven patients with Ph chromosome and no ce comprised the second group. The median age was 45 years (range: 20-74) and male to female ratio was 2:5. Two of the cases (Cases 21, 22) had received a prior course of inF before imatinib. Patients' characteristics are summarised in Table 1 and Table  2 .
There were no statistically significant differences in the basic characteristics of the patients comprising the two groups ( Table 3) . 
Conventional cytogenetics
conventional cytogenetic analyses were performed in the cytogenetic laboratory of Medical Biology Department of cerrahpas Medical Faculty after 24 h or overnight unstimulated culture of bone marrow. Gtl banding was applied and chromosome abnormalities were described according to the iScn 1995/2005 (3, 4). At least 20 metaphases were evaluated whenever possible.
Statistical analysis
All descriptive and comparative statistical analyses were carried out using SPSS v.11 for Windows (SPSS inc, chicago, USA). the groups were not normally distributed; we therefore used the non-parametric Mann-Whitney U test to compare different parameters in the two groups. A p value <0.05 was considered statistically significant.
Results and Dıscussıon
There were no statistically significant differences in the basic characteristics of the patients between the two groups as shown in Table 3 . the classical Ph translocation was observed in 17 cases, whereas variant Ph translocations were present in 3 patients; t(4;8;9;22)(q11;q13,q34;q11) in case 5, t(12;22)(p13;q11) in case 10, and t(7;22)(p22;q11) in case 19. the additional clonal chromosome abnormalities in Ph(+) cells of our cases are summarized in Table 4 . the additional abormalities were only numerical in 10 cases, whereas both structural and numerical abnormalities were observed in 10 18 Ph (%100) +8 (%83) 10
Ph (%100) +8 (%72), der(7;17)(q10;q10) (%17) 23
Ph (%100) +8 (%35), der(7;17)(q10;q10) (%41) 28
Ph (%100) +8 (%31), der(7;17)(q10;q10) (%25) Prior to imatinib cases. the most frequent abnormality was monosomy 21 which was observed in 7 cases (%35), followed by -17 in 6 cases (%30), -19 and +8 in 5 case each (%25) (in Ph(-) cells in one case each), -7, -8, -13, -15, -22, +Ph, and different marker chromosomes in 4 cases each (%20), -Y, -12, -14, -16, -20 in 3 cases each (%15), +Y, -10, -18 in 2 cases each (%10), and -X, -3, -9, +20, der(7;17)(q10;q10), der3?, der12? in one case each (%5). dmins were observed in 3 cases but in only Ph(-) cells in two of the cases (cases 13 and 14) and in Ph(+) cells in case 20. -Y, +Y, -11, del(7)(q11), and del(15)(q21) were observed in Ph(-) cells in one case each. Monosomy 21 has been observed in four successive samples of Case 1 and in two of Case 19. The findings of -Y, -7, -8, +8, -14, -15, -17, -18, +Ph, der(7;17)(q10;q10) and del(7)(q11) have been recorded in more than one samples in one case each.
in order to evaluate the impact of occurrance of ce on the prognosis and natural course of cMl during imatinib treatment we compared ce carriers (group i) with non-carriers (group ii) in terms of overall survival and treatment response. regressed back to ncR. three cases (cases 11, 13, and 15) had minimal (MinimalcR) (cases 11 and 13) and partial (PcR) (case 15) cytogenetic responses and eventually reached a ccR. case 14 once had a ccR but went back to PcR. cases 17, 18 and 19 had different MinorcRs during following. in 6 cases (cases 1, 13, 14, 15, 16, 19), chromosome abnormalities were observed before the imatinib onset, and in 2 (case 15 and 16) they disappeared after imatinib. in case 1, -17 and -21 were observed before the onset of imatinib and they persisted under imatinib treatment. While -17 had disappeared in the third and fourth samples, -21 was observed in all four samples of the case. in case 13, the marker chromosome, that had been observed prior to imatinib, had vanished in the later samples. however, new abnormalities like -17 and -21 emerged in the second sample in the 6 th month of imatinib therapy. in the third sample (12 th month of the therapy), these two abnormalities disappeared but +8 was observed in Ph(-) metaphases. in case 14, there were several monosomies before the imatinib onset and one of them, -Y, persisted in the second sample, in the 21 st month of imatinib. in case 19, there were some abnormalities in both Ph(+) and Ph(-) cells before imatinib, and -21, which was observed in Ph(+) cells in this sample, was observed again in both Ph(+) and Ph(-) cells in the second sample under imatinib.
From the major route abnormalities, we have observed +8 (25%), +Ph and -7 (20%), and -Y (27% of males) in our series.
Monosomy 21 was the most frequently seen abnormality in our series. it was observed in 7 cases (35%) and more than one samples of two cases. it persisted in all four bone marrow samples of case 1. it was also the most frequently seen abnormality in our group that had clonal chromosome abnormalities (ccA) in their Ph(-) cells as being recorded in 14 out of 35 cases (40%) (10) . there were 31 entries for -21 in cMl cases in Mitelman Database of chromosome Aberrations in cancer (9) at writing. Jiang et al. reported that they had observed -21 in 7.69% of their cases with classical Ph chromosomes and it was the most frequent abnormality in chronic phase patients as being seen in 10.26% of such cases (5) .
Monosomy 17 was observed in 6 cases (30%) in our series. In Case 1, it was present in 25% of the cells in the first bone marrow sample which had been taken before the onset of imatinib treatment, and persisted in 12% of the cells in the second sample which was taken after 21 months from the imatinib onset. But it vanished in the two later samples. to check our results, we performed FISH analysis with α-satellite probes for chromosome 17 to the second marrow sample of case 1 and observed monosomy 17 in 31% of the interphase cells. We got single signal for 17 in 19% in the control sample. Monosomy 17 is quite common in cMl with 96 recorded cases with classical Ph and 6 cases with variant Ph chromosomes in Mitelman Database (9) . Monosomy 17 was also observed in 10 cases out of 35 (29%) in our ccAs in Ph(-) cells series (10) . it could be even more prominent if it was traced by FiSh like monosomy of chromosome 7. in the group of patients with ce, nine patients showed no or minimal cytogenetic response to imatinib and had to be switched to another tyrosine kinase inhibitor. ccR could be achieved with three patients. in the second group, on the contrary, none of the patients developed a cytogenetic respose to imatinib but case 23's MinimalcR.
Conclusıons
Since the number of patients in either group is too low in our series, it is difficult to draw any solid conclusions about the impact of ce on the clinical course of the disease. Multicenter studies with large number of patients for each additional clonal chromosomal abnormality are certainly needed to detect frequently appearing abnormalities and clarify the exact role of clonal evolution on the progress of the disease. Despite its small size, our study raises monosomy 21 and 17 as two candidate clonal abnormalities that may have a positive or negative prognostic impact on cMl treated with imatinib. We, therefore recommend tracing monosomy 21 and 17 with FiSh in addition to classical cytogenetic analysis which is essential in monitoring of cMl.
